Vol 64, No 5 (2013)
Original paper
Published online: 2013-11-01

open access

Page views 2290
Article views/downloads 3992
Get Citation

Connect on Social Media

Connect on Social Media

Chromogranin A (CgA) in adrenal tumours

Piotr Glinicki, Wojciech Jeske, Lucyna Bednarek-Papierska, Anna Kasperlik-Załuska, Elżbieta Rosłonowska, Małgorzata Gietka-Czernel, Wojciech Zgliczyński
DOI: 10.5603/EP.2013.0018
Endokrynol Pol 2013;64(5):358-362.

Abstract

Introduction: Adrenal tumours can produce specific hormones and cause characteristic symptoms. The majority of adrenal incidentalomas
are clinically silent, but some may be malignant or pose other potential threats to life.
Chromogranin A (CgA) is the main, nonspecific marker of neuroendocrine tumours (NET). In the adrenals, CgA is produced by chromaffin
cells localised in the adrenal medulla. Therefore its measurement in blood might be used as a screening test for pheochromocytoma
after the exclusion of other various causes of an increased CgA level.
The aim of our study was to investigate plasma CgA concentration in various adrenal tumours.

Material and methods: EDTA2K plasma samples were obtained from 195 patients with adrenal tumours and from 50 blood donors. CgA
was measured in plasma-EDTA2K by immunoradiometric (IRMA) method.

Results: In the majority of patients with adrenal tumours not derived from neuroendocrine cells (chromaffin cells), except those with
significant hypercortisolaemia and some patients with adrenal carcinoma, the plasma CgA concentrations were below the cut-off value.
In adrenal tumours derived from chromaffin cells (pheochromocytoma), CgA levels were markedly elevated.

Conclusion: In differential diagnosis of adrenal tumours, non-increased CgA level might be useful initial screening evidence for the
exclusion of pheochromocytoma.

(Endokrynol Pol 2013; 64 (5): 358–362)